These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19757300)

  • 21. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

  • 22. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.
    Tirelli U; Errante D; Dolcetti R; Gloghini A; Serraino D; Vaccher E; Franceschi S; Boiocchi M; Carbone A
    J Clin Oncol; 1995 Jul; 13(7):1758-67. PubMed ID: 7541452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consolidation radiotherapy may improve outcomes in people with Hodgkin's disease achieving complete remission after combination chemotherapy.
    Specht L
    Cancer Treat Rev; 2004 Aug; 30(5):479-82. PubMed ID: 15245780
    [No Abstract]   [Full Text] [Related]  

  • 24. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of outcomes in studies of advanced Hodgkin's lymphoma.
    Johnson PW; Radford JA; Cullen MH; Sydes MR; Stenning SP; Hancock BW
    J Clin Oncol; 2006 Jul; 24(20):3309; author reply 3309-10. PubMed ID: 16829655
    [No Abstract]   [Full Text] [Related]  

  • 26. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
    Cheung MC; Hicks LK; Leitch HA
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):E22-5. PubMed ID: 20371439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [ABVD chemotherapy for Hodgkin lymphoma at a single institute].
    Ohshima R; Motomura S; Hashimoto C; Miyazaki T; Ito S; Takasaki H; Hyo R; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Tomita N; Fujita H; Fujisawa S; Harano H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2010 Dec; 51(12):1756-61. PubMed ID: 21258185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenging problems: coincident pregnancy, HIV infection, and older age.
    Connors JM
    Hematology Am Soc Hematol Educ Program; 2008; ():334-9. PubMed ID: 19074106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma.
    Hayden AR; Lee DG; Villa D; Gerrie AS; Scott DW; Slack GW; Sehn LH; Connors JM; Savage KJ
    Br J Haematol; 2020 Apr; 189(1):122-127. PubMed ID: 31822034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
    Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
    Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in early-stage Hodgkin's disease.
    Sarris AH
    J Clin Oncol; 1997 Jan; 15(1):411-2. PubMed ID: 8996173
    [No Abstract]   [Full Text] [Related]  

  • 35. [Role of response to first-line chemotherapy and of the primary lesion in Hodgkin lymphoma].
    Datsenko PV; Pan'shin GA; Sotnikov VM; Ivashin AV; Gombolevskiĭ VA; Golub SV; Evstikheev ÉV
    Vopr Onkol; 2012; 58(1):66-70. PubMed ID: 22629831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
    J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international randomized phase III HD16 trial conducted by the German Hodgkin Study Group].
    Nieder C
    Strahlenther Onkol; 2020 Apr; 196(4):414-415. PubMed ID: 32060584
    [No Abstract]   [Full Text] [Related]  

  • 38. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
    Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K
    Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
    Samant R; Alomary I; Alsaeed E; Al-Jasir B; Bence-Bruckler I; Cross P; Genest P; Huebsch L
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1166-70. PubMed ID: 19695788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.